Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma Full Text
Cancer Management and Research, 08/09/2012
Fisher R et al. – The BRAF inhibitor, vemurafenib, has demonstrated improved progression–free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF–V600 mutation. A BRAF–V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of profound clinical benefit for these patients.